Watch the On Demand SessionAI Won’t Negotiate With Your Payers

40% of new drug launches miss their two year sales forecast. Every single one hits a delay. AI is getting a lot of credit for fixing that, and some of it is earned. John Wollman, Komodo’s Head of Revenue Strategy, names five places AI is already worth the money in early commercialization and four where it will cost you.

• Five use cases where AI is delivering now: market research, HCP and KOL engagement, market access, brand strategy, and funding
• Four where it falls down: regulatory nuance, complex payer negotiation, brand storytelling, and reading adoption signals in a market with no data yet
• Why hybrid wins: AI drafts with human review hit a 90% MLR success rate, versus 20% for AI alone